Articles tagged with Cancer Medication
Researchers at Fox Chase Cancer Center have discovered that the drug Oltipraz can inhibit tumor growth by blocking blood vessel formation, while also increasing protective detoxification enzymes in the body. This dual mechanism of action may make Oltipraz a promising agent for both cancer prevention and treatment.
Researchers have characterized the structure of an Eph receptor tyrosine kinase bound to its corresponding ligand molecule, ephrin. This discovery provides a framework for developing potential drugs that could prevent cancer growth by blocking Eph signaling.
Researchers created molecular-scale computing circuits that can carry out basic computing operations, paving the way for tiny but powerful machines. These circuits have the potential to translate conversations on the fly or diagnose illnesses quickly, and could provide computing power for decades to come.
Scientists at Fred Hutchinson Cancer Center have discovered a potential new treatment for cancer and sickle-cell anemia by inhibiting gene silencing. The compound, splitomicin, effectively blocks the silencing of genes critical for healthy growth and may also be effective against certain cancers.
Researchers have discovered a promising new target for cancer chemotherapy by blocking cell uptake of polyamines with a heparan sulfate inhibitor. This approach, combined with a well-known anti-parasitic drug, shows great promise in reducing tumor formation.
Researchers found that the MabThera plus CHOP combination significantly improves overall survival for patients with aggressive non-Hodgkin's lymphoma, with a 70% survival rate after 26 months. The treatment is also effective in treating indolent NHL, with up to 55% of patients remaining in remission at four years.
A recent study at Duke University Medical Center found that letrozole, a new breast cancer treatment, was more effective than tamoxifen in shrinking tumors and reducing cell division. Patients taking letrozole showed significant tumor shrinkage and underwent fewer mastectomies compared to those on tamoxifen.
A new global survey found that 91% of physicians prescribe MabThera for NHL, with 62% citing proven efficacy in combination with chemotherapy. Non-Hodgkin's Lymphoma affects 1.5 million people worldwide, with Roche's MabThera showing improved survival rates when combined with conventional chemotherapy.
Researchers have discovered a genetically distinct form of leukemia that affects infants in their first year, characterized by abnormal gene activity and stuck cell development. The 'Mixed Lineage Leukemia' may be treatable with designer drugs targeting its specific weak points.
Researchers at Thomas Jefferson University developed a computer model showing that familial adenomatous polyposis (FAP) may begin when adult stem cells in the colon go out of control. The model suggests that an increase in stem cells triggers colon cancer, indicating that cancer may be a stem cell disorder.
Researchers at USC/Norris Comprehensive Cancer Center developed a test that analyzes tumor tissue to predict response to oxaliplatin and 5-FU chemotherapy. Patients with low ERCC1 and TS expression survived longer than those with high levels, indicating the potential for more effective treatment customization.
A new study found that early assessment of HIV-1 antiretroviral drug efficacy can predict long-term effectiveness. Patients with a continuous decline of HIV-1 concentrations within 0.72 log by day 6 after treatment initiation are likely to experience poor long-term responses.
Research suggests that Vioxx and Celebrex can enhance the effects of radiation on tumors by interfering with angiogenesis, a process that feeds tumor growth. This discovery has potential implications for treating various types of cancer and is being explored in ongoing clinical trials.
The NIH is funding three new synchrotron beamlines at Argonne National Laboratory to aid in the structural study of biological molecules. These facilities will be used to analyze protein structures that can help develop targeted cancer treatments.
Researchers at UNC will follow 1,000 newly diagnosed colon cancer patients for five years to study the impact of health literacy on patient outcomes. The study aims to improve survival rates and quality of life for patients with colon and lung cancers.
A new experimental drug called 2C4 has shown to significantly inhibit tumor growth in hormone-dependent and resistant prostate cancer tumors in mice. The monoclonal antibody targets the HER-2/neu protein, which controls cell growth and stimulates tumor growth.
Researchers at Ohio State University are studying a new treatment that blocks the production of Bcl-2, a protein overexpressed in many cancers, and found nearly half of 20 patients responding favorably. The treatment showed safety and induced disease remission in some patients.
Researchers at University Hospitals of Cleveland report promising results from Phase I trials of a new cancer drug, Combretastatin A4 Prodrug. The study showed significant reduction in tumor blood flow after infusion of the drug, with some patients experiencing complete remission and prolonged periods of freedom from disease progression.
Researchers at Thomas Jefferson University found that daily doses of Angiostatin, combined with radiation, caused a partial response in patients with advanced cancer. The treatment was well-tolerated, with few side effects reported.
Researchers developed a Herceptin-DM1 conjugate that targets HER2-positive breast cancer and shows complete regression in mice. Additionally, a new Bcr-Abl inhibitor called PD173955 demonstrates greater potency than Gleevec against leukemia cells, providing new hope for treatment-resistant cancers.
A recent survey conducted by the Fred Hutchinson Cancer Research Center found that nearly three-quarters of pediatric cancer patients in western Washington use alternative therapies. The most common types of alternative medicine used were herbal and high-dose vitamin supplements, which were reported to have substantial improvements in ...
ChemGenex Therapeutics has developed a new anticancer drug called Ceflatonin, which uses genomics to predict possible side effects and identify key genes for treatment. The company's research demonstrates that Ceflatonin affects specific genes and cellular pathways in leukemia and solid tumors.
Scientists develop 'smart' polymer drug carriers that target diseased cells, improving treatment outcomes for cancer, AIDS, and other diseases. The technology also enables controlled release of drugs over days, weeks, or years.
Researchers have identified Candidatus Endobugula sertula bacteria in Bugula neritina as the likely source of the anti-cancer compound Bryostatin 1. The study provides a new experimental system to unlock the potential of bryostatin drugs.
The rate of prostate cancer diagnosis has increased significantly, with only 3-5% of newly diagnosed patients having advanced disease. However, the impact of this shift on mortality rates is uncertain, as PSA screening can lead to over-treatment and unnecessary aggressive treatment.
The US FDA's priority review process for cancer drugs is significantly faster than its European counterpart, EMEA. In contrast to the EMEA's average approval time of over two years, the FDA approves cancer drugs on average within six months.
A pioneering combination of radiotherapy and chemotherapy has shown promising results in treating common cancers, including cervical, testicular, ovarian, bladder, and small cell lung cancer. Survival rates have increased by up to 18% with combined treatment, outperforming traditional radiotherapy alone.
The center investigates factors that predispose elderly patients to hospitalizations due to medication errors, as well as sociological and organizational causes of medication errors among physicians. Its research focuses on reducing internal bleeding and kidney failure caused by medication errors.
Exisulind, a new selective apoptotic anti-neoplastic drug, delays disease progression in men with recurrent prostate cancer by slowing the rise of PSA levels. The study also found significant inhibition of tumor growth in mice, suggesting potential as a treatment option for advanced prostate cancer.
The American College of Physicians announces new standards for manuscript submission, emphasizing author disclosure of sponsor involvement. These revised guidelines, developed by the International Committee of Medical Journal Editors, aim to prevent pharmaceutical companies from controlling study data and results.
Researchers at UGA have discovered an enzyme, GnT-V, that accelerates cancer invasion. Inhibiting this enzyme may slow cancer progression and even enable early detection through blood samples.
Researchers aim to identify and evaluate variations in 95 genes involved in cancer treatment, using DNA tests to predict a drug's effect on an individual. The goal is to tailor chemotherapy to each patient, improving treatment outcomes.
Scientists have solved the three-dimensional molecular structure of matriptase, a newly identified serine protease target for breast and prostate cancer drug development. This structural information is expected to facilitate the design of drugs that block or exploit the activity of matriptase and related proteases.
A Swedish study published in The Lancet found no association between antihypertensive drug treatments and an increased risk of cancer. The study analyzed 6600 patients with hypertension, randomly assigning them to three treatment strategies, and found no significant difference in cancer incidence between groups.
A new study suggests that modest dietary restrictions before fecal occult blood testing (FOBT) for colon cancer screening do not significantly impact completion rates. The report also notes that more severe restrictions may reduce test completion, highlighting the potential benefits of simplifying dietary advice for FOBT testing.
The Mayo Clinic study found that thalidomide can stop or slow the progression of multiple myeloma in patients newly diagnosed with this cancer. Thalidomide was previously used to treat advanced myeloma, but this is the first published report documenting its effectiveness as a first-line treatment for early-stage multiple myeloma.
PS-341, a proteasome inhibitor, has shown promising results in treating multiple myeloma and non-Hodgkin's lymphoma. The Phase I clinical trial found one complete response and several partial responses among patients, indicating the drug's potential as a treatment option.
A new study suggests tamoxifen may decrease risk of first breast cancer but increase risk of estrogen-receptor negative, more difficult-to-treat contralateral tumors in the opposite breast.
A UC Berkeley scientist proposes that chromosome reassortment, rather than genetic mutations, is the cause of cancer's tendency to develop drug resistance. This theory suggests aneuploid cells, with abnormal numbers of chromosomes, are more prone to producing drug-resistant cancer cells.
Researchers at Rutgers University have developed a new pharmaceutical 'smart bomb' that targets cancer cells using an improved prodrug delivery system. The system uses nitroreductase as the activating trigger, guaranteeing a direct hit on cancerous cells and minimizing damage to normal cells.
Two large studies followed US and British factory workers for extended periods, finding associations between formaldehyde exposure and increased risk of leukemia and lung cancer. However, the authors caution against drawing definitive conclusions about the carcinogenicity of formaldehyde in humans.
A new platinum-based cancer drug, BBR3464, has shown promising activity against ovarian cancer that is resistant to cisplatin. The drug, developed by Nicholas Farrell and his team, has been found to be significantly more potent than cisplatin and may offer new hope for the treatment of this devastating disease.
Researchers discovered gold compounds emitting fluorescent light for one million times longer than expected. The light is trapped inside the compound, leading to various applications including detecting diseases and producing sensors. Gold's unique properties also make it effective in treating rheumatoid arthritis and cancer.
The Emory-led research group aims to use naturally occurring sphingolipids to develop more effective compounds for cancer prevention and treatment. Sphingolipids have shown promise in controlling certain types of cancer, and the grant will focus on developing these compounds into new anti-cancer treatments.
Researchers have discovered a potential new target for therapy by understanding how Onyx-015 works against cancer cells. The study suggests that the drug's effectiveness may be linked to p14 ARF, which could lead to the development of new cancer treatments.
A research team at Johns Hopkins University has designed four different versions of vitamin D and tested them on mice, showing that one candidate can reduce tumor incidence by 28% and number of tumors by 63%. The results demonstrate the potential effectiveness of a chemically modified version of vitamin D in preventing cancer.
A 12-week study found that 49% of patients treated with Zyban had not used tobacco for the previous four weeks, compared to 26% in the placebo group. The three-month figures showed a slight increase in quit rates, but further research is needed.
A study found that prescribing sterile needles is ethical and clinically appropriate for injection drug users. Smoking daily can lead to impaired fasting glucose and type 2 diabetes. Long-term use of drugs promoting gastroesophageal reflux also increases the risk of esophageal adenocarcinoma.
Scientists at The Wistar Institute identified a new gene called chfr that establishes a previously unknown checkpoint in mitosis, found in half of human cancer cell lines. This discovery holds promise for predicting patient response to Taxol and developing more effective targeted drugs.
Researchers at Johns Hopkins presented Phase I study results for Taxoprexin DHA-paclitaxel, a novel taxane that tolerates high doses with minimal side effects. The drug delivers more therapeutic agent to tumor cells and less to healthy tissues, improving safety and effectiveness.
Researchers found a new class of drugs called selective apoptotic anti-neoplastic drugs (SAANDs) that can safely slow tumor growth in men with advanced prostate cancer. The study showed significant results with minimal side effects.
Researchers at the University of Pennsylvania Cancer Center have successfully conducted a Phase I clinical trial on combretastatin A4 phosphate, a vascular targeting agent. The study found that patients with solid tumors were able to safely tolerate the treatment and showed evidence of decreased blood flow to the tumor.
Researchers at the University of Glasgow have identified a complex of proteins that activate cell growth and division protein E2F, leading to excessive cell division and cancer. This breakthrough provides an opportunity to develop small molecule drugs that can arrest E2F activity and prevent tumour cell proliferation.
Researchers at Duke University developed heat-triggered liposomes that can deliver anti-cancer drugs to tumors, delaying growth and eradicating human tumors in mice. The new technology uses specially engineered liposomes that release their cargo rapidly when heated to temperatures just above normal body temperature.
The Yale Cancer Center will conduct a clinical trial of a new compound, indole 3 carbinol, to suppress HPV infections and prevent cervical cancer. A $1.3 million grant from the NCI will fund the study in 200 participants with chronic HPV infections.
A recent study by the Mayo Clinic found that 10 out of 16 men experienced a greater than 50% reduction in hot flashes while taking venlafaxine. The incidence of severe and very severe hot flashes was also significantly reduced.
Researchers found that tamoxifen causes the estrogen receptor to form a unique pocket that changes its response to the drug. New drugs targeting this pocket may offer hope to patients with breast cancer resistant to tamoxifen.
A new study from UCSF found that grapefruit juice can inhibit the body's absorption of certain drugs, including cancer medication Vinblastine and HIV protease inhibitor saquinavir. Patients taking these medications with grapefruit juice may experience increased levels of the drug in their blood.
Scientists are modifying bee venom to develop cancer treatments with fewer side effects than traditional drugs. The goal is to create immunotoxins that target cancer cells specifically, overcoming major drawbacks of chemotherapy.
UCSF researchers report that the osteoporosis prevention drug raloxifene drastically reduces the risk of breast cancer in postmenopausal women without increasing the risk of endometrial or uterine cancer. The study found a 70 percent reduction in breast cancer cases among participants taking raloxifene compared to those receiving placebo.